Atezolizumab Plus Axi-Cel Leads to Manageable Safety Profile in DLBCL


A manageable safety profile was demonstrated with the combination of atezolizumab plus an anti-CD19 chimeric antigen receptor T-Cell therapy in patients with refractory diffuse large B-cell lymphoma in the ZUMA-6 trial.

Caron Jacobson, MD

Caron Jacobson, MD

Atezolizumab (Tecentriq) plus axicabtagene ciloleucel (axi-cel; Yescarta), an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, demonstrated a manageable safety profile as treatment of patients with refractory diffuse large B-cell lymphoma (DLBCL) in the ZUMA-6 trial (NCT02926833), according to a presentation during the 2020 American Association for Cancer Research Annual Meeting.1

The phase I/II study evaluated the safety and efficacy of the combination, and the trial stratified 34 patients into 3 cohorts. After undergoing leukapheresis, all cohorts received a conditioning dose of 30 mg/m2/day of fludarabine plus cyclophosphamide at 500 mg/m2/day for 3 days, followed by an axi-cel infusion of 2 × 106 CAR T cells/kg. In phase 1, 1200 mg of atezolizumab was administered every 21 days for 4 doses, starting on either day 21, 14, or 1 post axi-cel infusion for cohorts 1, 2, and 3, respectively. After safety review, 28 patients were treated in phase 2 of the study, in which they received the phase 1 atezolizumab/axi-cel dosing schedule of cohort 3.

“The rationale for this study is that after T-cell infusion and upon T-cell activation, CAR T cells will upregulate PD-1,” lead author Caron Jacobson, MD, medical director of the Immune Effector Cell Therapy Program at Dana-Farber Cancer Institute and assistant professor of medicine at Harvard Medical School in Boston, Massachusetts, said during the presentation. The investigators administered atezolizumab in concordance with the upregulation of PD-1, which happens after T-cell activation. Checkpoint blockade may enhance the activity of CAR T cells.

The primary end point was incidence of dose-limiting toxicities (DLTs) for phase I and complete response (CR) rate for phase II. Secondary end points included incidence of adverse events (AEs), objective response rate, and CAR T-cell levels in the blood. Jacobson presented pooled data for the patients treated in phase I cohort 3 and phase II (n = 28). Median follow-up was 10.2 months.

Jacobson said results from phase I were presented at the American Society of Hematology Annual Meeting in 2018.2 For this cohort of patients, the median age was 58 years (range, 42-71) and all patients had an ECOG performance status of 0 or 1. The majority of patients had advanced-stage disease, 46% of patients had an International Prognostic Index score of 3 or 4, and 50% of patients had received 3 or more lines of prior therapy.

“All 34 patients enrolled in the phase I and II portions of the study received axi-cel and at least 1 dose of atezolizumab and 24 of 34 patients [74%] received all 4 doses of atezolizumab,” Jacobson said.

Baseline tumor biopsies were evaluated for PD-L1 expression using the Ventana PD-L1 assay. The median baseline tumor cell PD-L1 H score was 40 (range, 0-240). According to the immune infiltrate intensity score, 25% of patients had weak staining, 25% had moderate staining, and 39% had strong staining.

The most common grade 3 or greater treatment-emergent adverse events (TRAEs) occurring in 10% or more of patients was neutropenia (61%), anemia (54%), thrombocytopenia (36%) encephalopathy (25%), and hypophosphatemia (21%). Jacobson said that 39% of grade 3 or greater AEs were attributed to axi-cel, 14% were attributed to atezolizumab, and 25% were attributed to both.

One patient in phase I cohort 3 experienced a DLT of grade 4 thrombocytopenia and neutropenia that lasted longer than 30 days. There was 1 case of grade 5 AE of multiple organ dysfunction unrelated to axi-cel or atezolizumab reported in phase II. The patient developed cytomegalovirus pneumonia and viremia on day 22 following axi-cel infusion that subsequently progressed despite treatment with ganciclovir and was ultimately fatal.

Ninety-six percent of patients reported cytokine release syndrome (CRS) of any grade and 4% of patients experienced grade 3 CRS. There were no grade 4 or 5 CRS events observed. Median onset of CRS was 2 days and median duration was 7 days.

Sixty-eight percent of patients experienced any-grade neurologic events, with 29% experiencing grade 3 or greater severity. The most common neurologic events of any grade were encephalopathy (36%) and aphasia (14%). Median time to onset was 6 days (range, 1-23) and the median duration was 9 days (range, 2-60). Two neurologic events were ongoing at the time of data cut off: 1 case of grade 1 tremor and 1 case of grade 2 hypoesthesia.

Responses were seen in 75% of patients, and at the time of data cut off, 46% had ongoing response. “The median duration of response, progression-free survival, and overall survival have not been reached,” Jacobson said.

When considering all phase I and II portions of the study, 4 patients experienced late conversion, with 3 partial responses converting to complete responses and 1 stable disease converting to complete response.

Product characteristics were generally similar in ZUMA-6 compared with an earlier study, ZUMA-1.3 Jacobson reported that on a whole the, the CD4 to CD8 ratio for ZUMA-6 was similar with ZUMA-1 and there were no meaningful associations between product characteristics in clinical responses.

The kinetics of CAR T-cell expansion were also similar between ZUMA-6 and ZUMA-1 despite the addition of atezolizumab. The investigators reported that median area under the curve was also similar between the 2 studies.

Jacobson said that PD-L1 blockade with atezolizumab after axi-cel infusion has a manageable safety profile similar to that observed in the previous ZUMA-1 trial, with no significant incidence of AEs. Further, efficacy outcomes of axi-cel in combination with atezolizumab appeared to be comparable with those observed in patients treated with axi-cel alone.

“Additional studies involving axi-cel in combination with atezolizumab may be needed to establish an interaction between timing of checkpoint blockade and CAR T-cell treatment,” Jacobson concluded.


  1. Jacobson CA, Westin JR, Miklos DB, et al. Phase 1/2 primary analysis of ZUMA-6: Axicabtagene ciloleucel (Axi-Cel) in combination With atezolizumab (Atezo) for the treatment of patients (Pts) with refractory diffuse large B cell lymphoma (DLBCL). Presented at: 2020 American Association for Cancer Research Virtual Annual Meeting I: Virtual; April 27-28, 2020. Abstract CT055.
  2. Jacobson CA, Locke FL, Miklos DB, et al. End of phase 1 results from zuma-6: axicabtagene ciloleucel (Axi-Cel) in combination with atezolizumab for the treatment of patients with refractory diffuse large B cell lymphoma. Blood. 2018;132(suppl 1; abstr 626). doi: 10.1182/blood-2018-99-111523
  3. Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531-2544. doi: 10.1056/NEJMoa170744
Related Videos
Erika P. Hamilton, MD, and the Oncology Brothers presenting slides
Erika P. Hamilton, MD, and the Oncology Brothers presenting slides
Erika P. Hamilton, MD, and the Oncology Brothers presenting slides
Erika P. Hamilton, MD, and the Oncology Brothers presenting slides
Erika P. Hamilton, MD, and the Oncology Brothers presenting slides
Related Content